Paul B. Rosenberg

12.8k total citations · 3 hit papers
174 papers, 7.2k citations indexed

About

Paul B. Rosenberg is a scholar working on Psychiatry and Mental health, Physiology and Cognitive Neuroscience. According to data from OpenAlex, Paul B. Rosenberg has authored 174 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 104 papers in Psychiatry and Mental health, 47 papers in Physiology and 27 papers in Cognitive Neuroscience. Recurrent topics in Paul B. Rosenberg's work include Dementia and Cognitive Impairment Research (95 papers), Alzheimer's disease research and treatments (45 papers) and Schizophrenia research and treatment (20 papers). Paul B. Rosenberg is often cited by papers focused on Dementia and Cognitive Impairment Research (95 papers), Alzheimer's disease research and treatments (45 papers) and Schizophrenia research and treatment (20 papers). Paul B. Rosenberg collaborates with scholars based in United States, Canada and France. Paul B. Rosenberg's co-authors include Constantine G. Lyketsos, Milap A. Nowrangi, Michelle M. Mielke, Jeannie‐Marie Leoutsakos, Jacobo Mintzer, Esther S. Oh, Peter V. Rabins, Lea T. Drye, Anton P. Porsteinsson and Frederick E. Sieber and has published in prestigious journals such as JAMA, PLoS ONE and NeuroImage.

In The Last Decade

Paul B. Rosenberg

167 papers receiving 7.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand ¹⁸F-AV-45 (Flobetapir F 18)

2010 517 citations Dean F. Wong, Paul B. Rosenberg et al. Journal of Nuclear Medicine profile →
Effect of Citalopram on Agitation in Alzheimer Disease

2014 353 citations Anton P. Porsteinsson, Lea T. Drye et al. profile →
The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations

2017 322 citations Zahinoor Ismail, Jeffrey L. Cummings et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul B. Rosenberg United States	42	3.7k	2.0k	1.3k	902	860	174	7.2k
Mary Sano United States	59	4.9k 1.3×	3.4k 1.7×	1.5k 1.2×	1.1k 1.2×	1.5k 1.8×	252	12.8k
Orestes Vicente Forlenza Brazil	53	3.7k 1.0×	2.9k 1.5×	1.2k 0.9×	818 0.9×	1.4k 1.7×	288	9.3k
Zahinoor Ismail Canada	49	6.1k 1.6×	2.1k 1.0×	1.8k 1.4×	722 0.8×	658 0.8×	317	8.9k
Angelo Bianchetti Italy	47	3.2k 0.9×	2.3k 1.1×	1.4k 1.1×	438 0.5×	639 0.7×	178	7.8k
Philip S. Insel United States	39	4.5k 1.2×	3.3k 1.6×	1.6k 1.3×	457 0.5×	894 1.0×	110	7.0k
Davangere P. Devanand United States	50	5.0k 1.4×	2.6k 1.3×	1.8k 1.4×	1.3k 1.5×	1.3k 1.5×	204	9.7k
Breno S. Diniz Brazil	52	3.1k 0.8×	2.8k 1.4×	1.2k 0.9×	772 0.9×	1.2k 1.4×	172	8.8k
Marco Trabucchi Italy	60	2.9k 0.8×	2.8k 1.4×	1.5k 1.2×	713 0.8×	904 1.1×	308	12.7k
Jacobo Mintzer United States	40	3.7k 1.0×	1.3k 0.7×	700 0.6×	1.3k 1.5×	592 0.7×	137	6.0k
Mark A. Sager United States	55	3.9k 1.0×	3.1k 1.5×	1.9k 1.5×	242 0.3×	1.0k 1.2×	152	9.7k

Countries citing papers authored by Paul B. Rosenberg

Since Specialization

Citations

This map shows the geographic impact of Paul B. Rosenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul B. Rosenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul B. Rosenberg more than expected).

Fields of papers citing papers by Paul B. Rosenberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul B. Rosenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul B. Rosenberg. The network helps show where Paul B. Rosenberg may publish in the future.

Co-authorship network of co-authors of Paul B. Rosenberg

This figure shows the co-authorship network connecting the top 25 collaborators of Paul B. Rosenberg. A scholar is included among the top collaborators of Paul B. Rosenberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul B. Rosenberg. Paul B. Rosenberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hendrix, Suzanne, Mary Sano, Constantine G. Lyketsos, et al.. (2025). Cohen-mansfield agitation inventory total score as a measure of agitation and aggression in Alzheimer’s disease: A factor analysis. International Psychogeriatrics. 37(3). 100056–100056.

Nowrangi, Milap A., Jeannie‐Marie Leoutsakos, Haijuan Yan, et al.. (2025). Influence of cognitive, neuropsychiatric, and diagnostic factors on financial capacity: A longitudinal analysis of the ADNI cohort. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring. 17(1). e12583–e12583.

Perin, Jamie, Alden L. Gross, David Shade, et al.. (2024). Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial). International Journal of Geriatric Psychiatry. 39(6). e6108–e6108. 1 indexed citations

Locascio, Joseph J., Christopher González, Michael J Properzi, et al.. (2024). Longitudinal associations of apathy and regional tau in mild cognitive impairment and dementia: Findings from the Alzheimer's Disease Neuroimaging Initiative. Alzheimer s & Dementia Translational Research & Clinical Interventions. 10(1). e12442–e12442. 3 indexed citations

Spira, Adam P., Fangyu Liu, Vadim Zipunnikov, et al.. (2024). Evaluating a novel 24-hour rest/activity rhythm marker of preclinical β-amyloid deposition. SLEEP. 47(5). 4 indexed citations

Umoh, Mfon, Haijuan Yan, Jeannie‐Marie Leoutsakos, et al.. (2024). Preoperative Neurofilament Light Associated With Postoperative Delirium in Hip Fracture Repair Patients Without Dementia. Journal of the Academy of Consultation-Liaison Psychiatry. 66(1). 3–12. 1 indexed citations

Antonsdottir, Inga, Jill A. Rabinowitz, Jacek Urbanek, et al.. (2023). 24 h Rest/Activity Rhythms in Older Adults with Memory Impairment: Associations with Cognitive Performance and Depressive Symptomatology. Advanced Biology. 7(11). e2300138–e2300138. 3 indexed citations

Rosenberg, Paul B., Halima Amjad, Ryan G. Vandrey, et al.. (2023). Pilot trial of Dronabinol adjunctive treatment of agitation in Alzheimer’s disease (THC‐AD). Alzheimer s & Dementia. 19(S4). 1 indexed citations

Sagar, Ram, Esther S. Oh, Paul B. Rosenberg, et al.. (2023). Excitatory Neurons Derived from Human-Induced Pluripotent Stem Cells Show Transcriptomic Differences in Alzheimer’s Patients from Controls. Cells. 12(15). 1990–1990. 4 indexed citations

10.

Perin, Jamie, Nathan Herrmann, Olga Brawman‐Mintzer, et al.. (2023). Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study. Alzheimer s & Dementia Translational Research & Clinical Interventions. 9(3). e12403–e12403. 1 indexed citations

11.

Rosenberg, Paul B., et al.. (2022). Vestibular therapy to reduce falls in people with Alzheimer’s disease: study protocol for a pilot randomized controlled trial. Pilot and Feasibility Studies. 8(1). 167–167. 4 indexed citations

12.

Ehrhardt, Stephan, Anton P. Porsteinsson, Cynthia A. Munro, et al.. (2019). Escitalopram for agitation in Alzheimer's disease (S‐CitAD): Methods and design of an investigator‐initiated, randomized, controlled, multicenter clinical trial. Alzheimer s & Dementia. 15(11). 1427–1436. 34 indexed citations

13.

Marano, Christopher M., et al.. (2015). Interventions for Neuropsychiatric Symptoms in Neurocognitive Impairment Due to Alzheimer’s Disease. Harvard Review of Psychiatry. 23(5). 377–393. 30 indexed citations

14.

Soto, María, Sandrine Andrieu, Fati Nourhashémi, et al.. (2014). Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design. International Psychogeriatrics. 27(2). 181–197. 32 indexed citations

15.

Wong, Dean F., Paul B. Rosenberg, Yun Zhou, et al.. (2010). In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand ¹⁸F-AV-45 (Flobetapir F 18). Journal of Nuclear Medicine. 51(6). 913–920. 517 indexed citations breakdown →

16.

Drye, Lea T., Barbara K. Martin, Constantine Frangakis, et al.. (2010). Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS-2)?. International Journal of Geriatric Psychiatry. 26(6). 573–583. 22 indexed citations

17.

Rosenberg, Paul B. & C.G. Lyketsos. (2008). Mild cognitive impairment: searching for the prodrome of Alzheimer's disease. World Psychiatry. 7(2). 72–78. 48 indexed citations

18.

Rosenberg, Paul B., Michelle M. Mielke, JoAnn T. Tschanz, et al.. (2008). Effects of Cardiovascular Medications on Rate of Functional Decline in Alzheimer Disease. American Journal of Geriatric Psychiatry. 16(11). 883–892. 104 indexed citations

19.

Rosenberg, Paul B., Chiadi U. Onyike, Ira R. Katz, et al.. (2005). Clinical application of operationalized criteria for ‘Depression of Alzheimer's Disease’. International Journal of Geriatric Psychiatry. 20(2). 119–127. 32 indexed citations

20.

Rosenberg, Paul B., et al.. (2002). Repetitive Transcranial Magnetic Stimulation Treatment of Comorbid Posttraumatic Stress Disorder and Major Depression. Journal of Neuropsychiatry. 14(3). 270–276. 96 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact